例如:"lncRNA", "apoptosis", "WRKY"

Prognostic and clinicopathological significance of CXCL1 in cancers: a systematic review and meta-analysis.

Cancer Biol Ther. 2019 ;20(11):1380-1388. doi:10.1080/15384047.2019.1647056. Epub 2019 Aug 06
Zulei Zhang 1 , Yuting Chen 1 , Yaofei Jiang 2 , Yan Luo 2 , Hao Zhang 1 , Yakun Zhan 3
Zulei Zhang 1 , Yuting Chen 1 , Yaofei Jiang 2 , Yan Luo 2 , Hao Zhang 1 , Yakun Zhan 3
+ et al

[No authors listed]

Author information
  • 1 Department of the Graduate School, Nanchang University , Nanchang , Jiangxi , People's Republic of China.
  • 2 Department of Radiology, Second Affiliated Hospital of Nanchang University , Jiangxi , China.
  • 3 Department of Emergency and Critical Care Medicine, Second Affiliated Hospital of Nanchang University , Nanchang , Jiangxi , P.R. China.

摘要


Background The prognostic value of Chemokine (C-X-C motif) ligand 1 (CXCL1) in various types of cancer remains controversial. Here we aimed to evaluate the prognostic role of CXCL1 for cancer. Methods A comprehensively search of the PubMed, Embase, Web of Science, Wanfang and China National Knowledge Internet databases was conducted to retrieve eligible studies meeting the inclusion criteria. Overall survival (OS), progression-free survival (PFS) and various clinicopathological parameters were defined as endpoints. Stata SE12.0 software was used for quantitative meta-analysis. Results A total of 17 studies encompassing 2265 cancer patients were included. Our meta-analysis showed that patients with higher CXCL1 expression had significantly shorter OS, according to both multivariate (HR 1.51, 95% CI 1.19-1.83, P < .01) and univariate analysis (HR 2.08, 95% CI 1.62-2.54, P < .01). Furthermore, higher CXCL1 expression was significantly correlated with advanced TNM stage and lymph node metastasis (both P < .05). Conclusions High CXCL1 expression is a risk factor for cancer prognosis indicating a poor OS, and advanced TNM stage and lymph node metastasis, demonstrating that it may be a promising prognostic biomarker for different cancers.

KEYWORDS: CXCL1, GRO alpha, cancer, prognosis